News

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human ...
TipRanks on MSN2d
Telomir Pharmaceuticals Joins BIO Convention for Partnerships
An announcement from Telomir Pharmaceuticals, Inc. ( ($TELO) ) is now available. On June 2, 2025, Telomir Pharmaceuticals announced its ...
Fierce Pharma6d
Drugmakers, trade groups and others voice concerns with pharma-specific tariffs
Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...
Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor
Transpire Bio Inc., a U.S.-based, integrated clinical-stage biopharmaceutical company focused on developing inhaled ...
Fierce Pharma13d
CDMO Samsung Biologics telegraphs spinoff of biosim unit
In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...
JD Supra6d
FDA Approves Bio-Thera and Hikma’s Ustekinumab Biosimilar
On May 22, 2025, the FDA approved Bio-Thera Solutions and Hikma Pharmaceuticals’ ustekinumab biosimilar, STARJEMZA® (ustekinumab-hmny) ...
Morningstar19d
WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA
2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its partner CANbridge Pharmaceuticals on the ...